After Tilray, Aurora also receives a new cannabis production license in Germany

Aurora Cannabis strengthens its position in the German cannabis industry after obtaining new medical cannabis production licenses.

The existing Aurora plant in Leuna, Saxony-Anhalt, has been operational since 2021 and produces approximately 1,000 kg of flowers annually for medical cannabis. The new licenses include authorizations for research and development, allowing Aurora to test up to seven additional new cultivars at its EU GMP facility in Leuna. This expansion is expected to enhance the company's product portfolio and strengthen its leading position in the European market.

Michael Simon, president of Aurora Europe, expressed his gratitude to the German government for its support and Investment in medical cannabis growth. He highlighted that the enhanced license reflects Aurora's commitment to providing high-quality cannabis and its strategic objective to leverage global cultivation expertise locally.

Aurora, along with Tilray and Demecan, is one of the top three medical cannabis producers in Germany. The recent licenses granted to Aurora and Tilray highlight the competitive nature and rapid evolution of the German cannabis market. Tilray, through its subsidiary Aphria RX, has been active in Germany since March 2019 and has recently obtained the first new cultivation license from cannabis dispensed under the new legislation.

Germany's role in the European cannabis market

The New German cannabis legislation is a major step for the European cannabis industry. By reclassifying cannabis and permitting personal possession and cultivation, Germany is paving the way for a regulated commercial supply chain. The law, which has been implemented in stages, began with the legalization of personal possession and cultivation on April 1st, followed by The creation of cannabis cultivation clubs July 1st. These changes reflect a broader trend in Europe, where several countries, including Switzerland, the Czech Republic, Malta, and the Netherlands, are also exploring or implementing various cannabis markets.

The legalization of flowers Cannabis for medical purposes in Germany dates back to 2017, with an annual national production ceiling of 10,400 kg. Since then, the demand for medical cannabis has continued to increase, driven by imports from countries like Canada. In the first three quarters of 2017, Germany imported 530 kg of cannabis. By the end of the first three quarters of 2023, this figure had jumped to 14,315 kg. This significant increase in imports highlights the growing acceptance and demand for medical cannabis in Germany.

For Canadian cannabis companies like Aurora and Tilray, expansion into the German market offers a strategic solution to supply problems stemming from Excess supply in the Canadian market. By establishing themselves in Germany, these companies can bypass the numerous export requirements and the costs associated with shipping products from Canada. This local production capability allows them to better serve the booming European market.

Aurora's expansion into Germany is not an isolated initiative. It is part of a broader strategy to establish a strong presence in the European market, which is considered an essential growth sector for the cannabis industry. Germany, with its strong regulatory framework and its significant potential market, is at the forefront of this European cannabis expansion.